Antibiotic resistance of Helicobacter pylori in pediatric patients - 10 years' experience (CROSBI ID 200862)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Hojšak, Iva ; Kos, Tea ; Dumančić, Jelena ; Mišak, Zrinjka ; Jadrešin, Oleg ; Jaklin Kekez, Alemka ; Lukić Grlić, Amarela ; Kolaček, Sanja
engleski
Antibiotic resistance of Helicobacter pylori in pediatric patients - 10 years' experience
The aim of this study was to assess the pattern of evolution of resistance to antibiotics in Helicobacter pylori isolated from children who underwent upper endoscopy with antral biopsy during a 10-year period (2001-2010). We retrospectively analyzed data of all children (n = 3, 008) who underwent upper endoscopy during the observed period at the Children's Hospital Zagreb, a university tertiary medical center. We calculated the rate, antibiotic susceptibility and risk factors for the H. pylori infection in our cohort. Antral biopsy was performed in 2, 313 (76.89%) patients. Altogether, 382 (16.51%) children had positive biopsy for H. pylori (histology and/or culture). There was no significant difference in the incidence of H. pylori during 10 years of observation (p = 0.21). Infected children compared to non-infected group were older (p = 0.005), and had more often antral nodularity (p < 0.0001), and duodenal ulcer (p = 0.002). Altogether, 22.4% of treatment-naïve patients had strains resistant to tested antibiotics: majority to azithromycin (17.9%), followed by clarithromycin (11.9%), metronidazole (10.1%) and amoxicillin (0.6%). In the eradication failure group, 9/11 of children had strains resistant to tested antibiotics, mostly to metronidazole (7/11), followed by azithromycin (3/11) and clarithromycin (1/11). No correlation was found between age or gender and antibiotic resistance (p = 0.32, for both). In conclusion, our data strongly support current guidelines which recommend antibiotic susceptibility testing prior to eradication therapy. Based on our results we recommend the use of amoxicillin- metronidazole- based regimen as the first-line therapy in our study population.
antibiotic resistance ; Helicobacter pylori ; pediatric patients
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
171 (9)
2012.
1325-1330
objavljeno
0340-6199
1432-1076
10.1007/s00431-012-1722-8
Povezanost rada
Kliničke medicinske znanosti